Taipei Medical University

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Lee O
------>authors3_c=
------>paper_class1=2
------>Impact_Factor=None
------>paper_class3=0
------>paper_class2=0
------>vol=
------>confirm_bywho=amel
------>insert_bywho=hpw
------>Jurnal_Rank=None
------>authors4_c=
------>comm_author=
------>patent_EDate=None
------>authors5_c=
------>publish_day=1
------>paper_class2Letter=None
------>page2=
------>medlineContent=
------>unit=G0100
------>insert_date=20080324
------>iam=4
------>update_date=None
------>author=???
------>change_event=4
------>ISSN=
------>authors_c=
------>score=146
------>journal_name=Abst. 1999 PSCT Med. Chem. Sym.
------>paper_name=Selective cytotoxicity of novel Azatyrosinamides.
------>confirm_date=20081217
------>tch_id=096021
------>pmid=16039850
------>page1=39
------>fullAbstract=This study aims to develop novel azatyrosinamide compounds structurally modified from ras-specific antioncogenic azatyrosine. Analogues 4-15 were prepared and their inhibition on the growth of wild-type and ras-transformed NIH 3T3 cell lines was compared. Compound 12 was found to be the most active with IC50 16.5+/-2.2 microM which is 458-fold more potent than that of azatyrosine. The selective toxicity, defined as IC(50 wild-type)/IC(50 ras-transformed) for this compound was 138.5.
------>tmu_sno=None
------>sno=17312
------>authors2=Li YI
------>authors3=Hwang CF
------>authors4=Wang HP
------>authors5=
------>authors6=
------>authors6_c=
------>authors=Lee O
------>delete_flag=0
------>SCI_JNo=None
------>authors2_c=
------>publish_area=2
------>updateTitle=Selective cytotoxicity of azatyrosinamides against ras-transformed NIH 3T3 cells.
------>language=2
------>check_flag=None
------>submit_date=None
------>country=NULL
------>no=
------>patent_SDate=None
------>update_bywho=None
------>publish_year=1999
------>submit_flag=None
------>publish_month=1
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z